SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRC
Status:
Not yet recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
The study is a phase II clinical study. The purpose of the study is to evaluate the efficacy
and safety of SBRT combined with Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line
Treatment in mCRC.